| Ms Christine Nicole Poe, ARNP | |
|
1200 W Carmel Dr Ste 103, Carmel, IN 46032-8707 | |
| (317) 709-0706 | |
| (888) 505-6818 |
| Full Name | Ms Christine Nicole Poe |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 24 Years |
| Location | 1200 W Carmel Dr Ste 103, Carmel, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053584276 | NPI | - | NPPES |
| 200939430 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 71001075A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Community Hospital East | Indianapolis, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Healogics Specialty Physicians Of Indiana Llc | 3678874567 | 14 |
| Brookside Medical Home Visits Llc | 8325389984 | 3 |
News Archive
The finding by the Health and Human Services Inspector General emphasizes the extent of medication errors, preventable infections and other care issues in skilled nursing facilities. Also, California's Sutter Health system says it has developed a program to make end of life care both more caring and more economical.
In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.
Personal myths, aversive racism, heat and retaliation in baseball, and the power of writing about personal trauma - these are just a few of the research areas of the winners of the 2012 annual awards from the Society for Personality and Social Psychology (SPSP). Each of the recipients has made a unique and significant contribution to understanding the individual and social factors shaping people's personalities, interactions, and behaviors.
Gilead Sciences, Inc. announced today its results of operations for the quarter ended September 30, 2010. Total revenues for the third quarter of 2010 were $1.94 billion, up 8 percent compared to total revenues of $1.80 billion for the third quarter of 2009. Net income for the third quarter of 2010 was $704.9 million, or $0.83 per diluted share, compared to net income for the third quarter of 2009 of $673.0 million, or $0.72 per diluted share.
Babies born after being exposed to both opioids and benzodiazepines before birth are more likely to have severe drug withdrawal, requiring medications like morphine for treatment, compared to infants exposed to opioids alone, according to a Vanderbilt University Medical Center study published in Hospital Pediatrics.
› Verified 3 days ago
| Entity Name | Healogics Specialty Physicians Of Indiana Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396145975 PECOS PAC ID: 3678874567 Enrollment ID: O20151218000074 |
News Archive
The finding by the Health and Human Services Inspector General emphasizes the extent of medication errors, preventable infections and other care issues in skilled nursing facilities. Also, California's Sutter Health system says it has developed a program to make end of life care both more caring and more economical.
In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.
Personal myths, aversive racism, heat and retaliation in baseball, and the power of writing about personal trauma - these are just a few of the research areas of the winners of the 2012 annual awards from the Society for Personality and Social Psychology (SPSP). Each of the recipients has made a unique and significant contribution to understanding the individual and social factors shaping people's personalities, interactions, and behaviors.
Gilead Sciences, Inc. announced today its results of operations for the quarter ended September 30, 2010. Total revenues for the third quarter of 2010 were $1.94 billion, up 8 percent compared to total revenues of $1.80 billion for the third quarter of 2009. Net income for the third quarter of 2010 was $704.9 million, or $0.83 per diluted share, compared to net income for the third quarter of 2009 of $673.0 million, or $0.72 per diluted share.
Babies born after being exposed to both opioids and benzodiazepines before birth are more likely to have severe drug withdrawal, requiring medications like morphine for treatment, compared to infants exposed to opioids alone, according to a Vanderbilt University Medical Center study published in Hospital Pediatrics.
› Verified 3 days ago
| Entity Name | Brookside Medical Home Visits Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306339742 PECOS PAC ID: 8325389984 Enrollment ID: O20190408002379 |
News Archive
The finding by the Health and Human Services Inspector General emphasizes the extent of medication errors, preventable infections and other care issues in skilled nursing facilities. Also, California's Sutter Health system says it has developed a program to make end of life care both more caring and more economical.
In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.
Personal myths, aversive racism, heat and retaliation in baseball, and the power of writing about personal trauma - these are just a few of the research areas of the winners of the 2012 annual awards from the Society for Personality and Social Psychology (SPSP). Each of the recipients has made a unique and significant contribution to understanding the individual and social factors shaping people's personalities, interactions, and behaviors.
Gilead Sciences, Inc. announced today its results of operations for the quarter ended September 30, 2010. Total revenues for the third quarter of 2010 were $1.94 billion, up 8 percent compared to total revenues of $1.80 billion for the third quarter of 2009. Net income for the third quarter of 2010 was $704.9 million, or $0.83 per diluted share, compared to net income for the third quarter of 2009 of $673.0 million, or $0.72 per diluted share.
Babies born after being exposed to both opioids and benzodiazepines before birth are more likely to have severe drug withdrawal, requiring medications like morphine for treatment, compared to infants exposed to opioids alone, according to a Vanderbilt University Medical Center study published in Hospital Pediatrics.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Christine Nicole Poe, ARNP 1200 W Carmel Dr Ste 103, Carmel, IN 46032-8707 Ph: (317) 709-0706 | Ms Christine Nicole Poe, ARNP 1200 W Carmel Dr Ste 103, Carmel, IN 46032-8707 Ph: (317) 709-0706 |
News Archive
The finding by the Health and Human Services Inspector General emphasizes the extent of medication errors, preventable infections and other care issues in skilled nursing facilities. Also, California's Sutter Health system says it has developed a program to make end of life care both more caring and more economical.
In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.
Personal myths, aversive racism, heat and retaliation in baseball, and the power of writing about personal trauma - these are just a few of the research areas of the winners of the 2012 annual awards from the Society for Personality and Social Psychology (SPSP). Each of the recipients has made a unique and significant contribution to understanding the individual and social factors shaping people's personalities, interactions, and behaviors.
Gilead Sciences, Inc. announced today its results of operations for the quarter ended September 30, 2010. Total revenues for the third quarter of 2010 were $1.94 billion, up 8 percent compared to total revenues of $1.80 billion for the third quarter of 2009. Net income for the third quarter of 2010 was $704.9 million, or $0.83 per diluted share, compared to net income for the third quarter of 2009 of $673.0 million, or $0.72 per diluted share.
Babies born after being exposed to both opioids and benzodiazepines before birth are more likely to have severe drug withdrawal, requiring medications like morphine for treatment, compared to infants exposed to opioids alone, according to a Vanderbilt University Medical Center study published in Hospital Pediatrics.
› Verified 3 days ago
Mrs. Heather M Caul, AG-ACNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 13345 Illinois St, Carmel, IN 46032 Phone: 317-396-1300 Fax: 317-352-3417 | |
Jennifer M Spors, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 11700 N Meridian St, Carmel, IN 46032 Phone: 317-688-2000 | |
Gaelle Maviluka Bulabula, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1217 S Rangeline Rd, Carmel, IN 46032 Phone: 317-846-4818 | |
Mrs. Margaret K Vanderveen, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 12289 Hancock St Ste 34, Carmel, IN 46032 Phone: 317-815-8950 Fax: 317-815-8951 | |
Taylor K Schub, WHNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 13420 N Meridian St Ste 400, Carmel, IN 46032 Phone: 317-573-7050 Fax: 317-573-7098 | |
Lesley L Leggington, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 12175 Silvara Ct, Carmel, IN 46032 Phone: 317-370-6656 | |
Molly Taylor, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 221 N Rangeline Rd, Carmel, IN 46032 Phone: 317-343-0611 |